COMMUNIQUÉS West-GlobeNewswire

Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer

23/10/2024 - 14:00

Dr. Rahul Rajan Kaushik is an accomplished technical operations leader with over two decades of expertise in Chemistry, Manufacturing and Controls (CMC) WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Disc Medicine [...]

WITHIN Health, Inc. Launches Accessible Thyroid Reboot Series to Reach Thousands of Women

23/10/2024 - 09:02

A self-paced program designed to help women with hypothyroidism and thyroidectomy regain control of their health through holistic methods MAHWAH, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- WITHIN Health, founded by [...]

Nxera Pharma Wins Biotech Company of the Year and Financing Deal of the Year at the Citeline Japan Awards 2024

23/10/2024 - 09:00

Tokyo, Japan and Cambridge, UK, 23 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce that it has won Biotech Company of [...]

DARZALEX® (daratumumab)-SC based quadruplet regimen approved by the European Commission for patients with newly diagnosed multiple myeloma who are transplant-eligible

23/10/2024 - 08:59

Phase 3 PERSEUS study of daratumumab subcutaneous (SC) formulation in combination with bortezomib, lenalidomide and dexamethasone induction and consolidation, followed by daratumumab SC and lenalidomide maintenance [...]

NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA

23/10/2024 - 08:56

TORONTO and HAIFA, Israel, Oct. 23, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “ Company ” or “ NurExone ”), a biopharmaceutical company developing exosome-based [...]

Eurobio Scientific: Communiqué de mise à disposition du public des informations relatives aux caractéristiques notamment juridiques, financières et comptables de la société Eurobio Scientific SA

23/10/2024 - 08:30

COMMUNIQUÉ DU 23 OCTOBRE 2024 OFFRE PUBLIQUE D’ACHAT VISANT LES ACTIONS DE LA SOCIÉTÉ INITIÉE PAR LA SOCIÉTÉ EB DEVELOPMENT AGISSANT DE CONCERT AVEC IK X LUXCO 3 S.A R.L, EUROBIONEXT, FPCI PEPITES ET TERRITOIRES, [...]

COMMUNIQUÉ RELATIF À LA MISE À DISPOSITION DES INFORMATIONS RELATIVES AUX CARACTÉRISTIQUES, NOTAMMENT JURIDIQUES, FINANCIÈRES ET COMPTABLES D’EB DEVELOPMENT DANS LE CADRE DE L’OFFRE PUBLIQUE D’ACHAT VISANT LES ACTIONS D'EUROBIO SCIENTIFIC

23/10/2024 - 08:30

COMMUNIQUÉ DU 23 OCTOBRE 2024 RELATIF À LA MISE À DISPOSITION DES INFORMATIONS RELATIVES AUX CARACTÉRISTIQUES, NOTAMMENT JURIDIQUES, FINANCIÈRES ET COMPTABLES D’EB DEVELOPMENT DANS LE CADRE DE L’OFFRE PUBLIQUE D’ACHAT [...]

Spur Therapeutics Showcases Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Oral Presentation at ESGCT 31st Annual Congress

23/10/2024 - 08:00

Data highlight potential of FLT201 to set new standard of care for Gaucher disease Dramatic and durable reductions observed in lyso-Gb1, an established biomarker of clinical response, in patients with persistently high [...]

Smart Immune Announces Recommended SMART101 Dose for Adult Cancer Proof-of-Concept Trials

23/10/2024 - 07:01

ReSET-02 dose escalation Phase I is completed Phase II PoC randomized segment is starting No dose-limiting toxicities, no safety or tolerability issues The highest dose is to be used in both hematological and solid [...]

Smart Immune détermine la dose recommandée de SMART101 pour ses essais cliniques en oncologie

23/10/2024 - 07:01

La phase I d'escalade de dose de ReSET-02 chez des adultes souffrant de cancers hématologiques est terminée. Le segment randomisé de la phase II de cet essai est en cours. Aucune toxicité limitant la dose, le profil de [...]

Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

23/10/2024 - 07:00

PARIS, FRANCE, 23 October 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its performance for the year to date and the third quarter of 2024. YTD 2024 YTD 2023 [...]

Ipsen enregistre une forte dynamique commerciale au cours des neuf premiers mois de l'année 2024 et revoit à la hausse ses prévisions pour l'exercice en cours

23/10/2024 - 07:00

PARIS, FRANCE, 23 octobre 2024 - Ipsen (Euronext : IPN ; ADR : IPSEY), groupe biopharmaceutique mondial de spécialité, présente aujourd’hui son chiffre d’affaires réalisé depuis le début de l’exercice et pour le [...]

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months

23/10/2024 - 07:00

Group sales grew by 6% 1 at constant exchange rates (CER) (2% in CHF) in the first nine months, driven by the high demand for both our medicines and diagnostics; excluding COVID-19-related products, sales increased by 8 [...]

Press Release Biocartis NV: Biocartis announces six Idylla™ abstracts to be presented at AMP 2024 Annual Meeting

23/10/2024 - 07:00

PRESS RELEASE - 23/10/2024, 07:00 CEST Biocartis announces six Idylla™ abstracts to be presented at AMP 2024 Annual Meeting Mechelen, Belgium, 23 October 2024 – Biocartis NV (“Biocartis”), an innovative molecular [...]

Press release: SEQUANA MEDICAL ANNOUNCES ADDITIONAL CONVERTIBLE FINANCING OF UP TO EUR 1.0 MILLION FROM EXISTING INVESTORS

23/10/2024 - 07:00

SEQUANA MEDICAL ANNOUNCES ADDITIONAL CONVERTIBLE FINANCING OF UP TO EUR 1.0 MILLION FROM EXISTING INVESTORS Ghent, Belgium, 23 October 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana [...]

Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies

23/10/2024 - 06:01

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim safety and proof-of-concept [...]

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

23/10/2024 - 04:15

LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through transformative RNA therapies based on its [...]

Synergy CHC Corp. Prices $10.35 Million Initial Public Offering

23/10/2024 - 01:25

WESTBROOK, Maine, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (“Synergy”), a provider of consumer health care, beauty, and lifestyle products, announced today the pricing of an initial public offering of 1,150, [...]

Conavi Medical Corp. Engages ICP Securities Inc. for Automated Market Making Services

22/10/2024 - 22:45

TORONTO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- CONAVI MEDICAL CORP. (TSXV: CNVI) (“ CONAVI MEDICAL ” or the “ Company ”), a commercial stage company focused on designing, manufacturing, and marketing imaging technologies to [...]